As of November 14, 2026, Atrium Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 27, 2026 (Form 8-K, February 27, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Atrium Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Atrium Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-27. Every row below is cited to the filing it comes from, and this page adds each new change as Atrium Therapeutics, Inc. files it.
Also on the record for Atrium Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by Sessa Capital IM, L.P. | 8.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 8.6% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 5.6% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.2% of the class | 5%+ stakes | Source |
| April 8, 2026 | Stake report, Schedule 13G, by T. Rowe Price Associates, Inc. | 10% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Atrium Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Atrium Therapeutics, Inc. and the records around it.
Atrium Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Sessa Capital IM, L.P. also filed stake reports on 3 other companies: Sotera Health Co (Aug 2026), TreeHouse Foods, Inc. (Jan 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Evommune, Inc. (Nov 2026), Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026)
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
Watch Atrium Therapeutics, Inc.
Get an email when Atrium Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Atrium Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Atrium Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Atrium Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-27 | Reported | not named in the filing | 8-K, 2026-02-27 |
New leaders reset buying decisions — get the Full Report on Atrium Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Atrium Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Atrium Therapeutics, Inc.Every change, in the filing's words
Reported
On February 26, 2026, in connection with the Distribution, the following people were elected as directors: Carsten Boess W. Michael Flanagan Simona Skerjanec Troy Wilson Class I of the Board consists of Ms. Skerjanec and Mr. Boess, and their respective terms will expire at the Company's first annual meeting of stockholders to be held after the completion of the Distribution.
- Class II of the Board consists of Mr. Wilson and Mr. Flanagan, and their respective terms will expire at the Company's second annual meeting of stockholders to be held after the completion of the Distribution.
- Mr. Boess, Ms. Skerjanec and Mr. Wilson were appointed to serve as members of the Audit Committee of the Board.
- Ms. Boyce, Ms. Skerjanec and Mr. Wilson were appointed to serve as members of the Human Capital Management Committee of the Board.
- Employment Agreements with Certain Executive Officers On February 26, 2026, the Company entered into employment agreements with each of the executive officers set forth above.
- Certain Compensatory Plans As described in the Information Statement, certain compensatory plans in which the Company's executive officers and directors will participate have been adopted by the Company in connection with the Separation and Distribution.
- The Company's 2026 Incentive Award Plan and 2026 Employee Stock Purchase Plan are each described in the Information Statement under "Executive Compensation - 2026 Incentive Award Plan," and "Executive Compensation - 2026 Employee Stock Purchase Plan," respectively.
Tools for this story
Each opens in a new tab, filled in for Atrium Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
